LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 30

Search options

  1. Article ; Online: Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis.

    Cortazar, Frank B / Cerda, Jorge / Dhanani, Rahim / Roglieri, Joseph / Santoriello, Dominick

    Kidney international reports

    2023  Volume 8, Issue 8, Page(s) 1687–1691

    Language English
    Publishing date 2023-05-29
    Publishing country United States
    Document type Case Reports
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2023.05.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The Fate of Plasma Exchange and Glucocorticoid Dosing in ANCA-Associated Vasculitis After PEXIVAS.

    Cortazar, Frank B / Niles, John L

    American journal of kidney diseases : the official journal of the National Kidney Foundation

    2020  Volume 76, Issue 4, Page(s) 595–597

    MeSH term(s) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy ; Glucocorticoids ; Humans ; Plasma Exchange ; Plasmapheresis
    Chemical Substances Glucocorticoids
    Language English
    Publishing date 2020-04-08
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 604539-x
    ISSN 1523-6838 ; 0272-6386
    ISSN (online) 1523-6838
    ISSN 0272-6386
    DOI 10.1053/j.ajkd.2020.03.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Reply.

    Cortazar, Frank B / Niles, John L

    Arthritis & rheumatology (Hoboken, N.J.)

    2017  Volume 69, Issue 10, Page(s) 2095–2096

    MeSH term(s) Antibodies, Antineutrophil Cytoplasmic ; Autoantibodies ; B-Lymphocytes ; Immunoglobulin G ; Rituximab
    Chemical Substances Antibodies, Antineutrophil Cytoplasmic ; Autoantibodies ; Immunoglobulin G ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2017-08-15
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.40210
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan.

    Cortazar, Frank B / Niles, John L / Jayne, David R W / Merkel, Peter A / Bruchfeld, Annette / Yue, Huibin / Schall, Thomas J / Bekker, Pirow

    Kidney international reports

    2023  Volume 8, Issue 4, Page(s) 860–870

    Abstract: Introduction: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased ... ...

    Abstract Introduction: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1.73 m
    Methods: eGFR was determined at baseline and over the course of the trial. Changes in eGFR were compared between the 2 treatment groups.
    Results: In ADVOCATE, 27 of 166 patients (16%) in the avacopan group and 23 of 164 patients (14%) in the prednisone group had a baseline eGFR ≤20 ml/min per 1.73 m
    Conclusion: Among patients with baseline eGFR ≤20 ml/min per 1.73 m
    Language English
    Publishing date 2023-02-03
    Publishing country United States
    Document type Journal Article
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2023.01.039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial.

    Zonozi, Reza / Cortazar, Frank B / Jeyabalan, Anushya / Sauvage, Gabriel / Nithagon, Pravarut / Huizenga, Noah R / Rosenthal, Jillian M / Sipilief, Alexander / Cosgrove, Katherine / Laliberte, Karen A / Rhee, Eugene P / Pendergraft, William F / Niles, John L

    Annals of the rheumatic diseases

    2024  Volume 83, Issue 3, Page(s) 351–359

    Abstract: ... schedule rituximab. In the B cell arm, rituximab was reinfused upon B cell repopulation; in the ANCA arm ... of patients had a clinical relapse in the B cell arm, compared with 20.5% (95% CI 11.9 to 34.1) in the ANCA ... deaths did not differ. The number of SAEs due to COVID-19 was higher in the B cell arm (p=0.049 ...

    Abstract Objective: To compare two long-term remission maintenance strategies for antineutrophil cytoplasmic antibody (ANCA) vasculitis.
    Methods: We conducted a prospective, single-centre, open-label, randomised controlled trial of patients with ANCA vasculitis in remission after completing at least 2 years of fixed-schedule rituximab. In the B cell arm, rituximab was reinfused upon B cell repopulation; in the ANCA arm, rituximab was reinfused upon significant rise in ANCA level. Evaluations were conducted every 3 months. The primary endpoint was clinical relapse, defined as a modified BVAS/WG >0 by 36 months. Secondary endpoints included serious adverse events (SAEs) and rituximab exposure.
    Results: 115 patients were enrolled. Median follow-up time was 4.1 years (IQR 2.5-5.0). By Kaplan-Meier analysis, 4.1% (95% CI 1.0 to 15.6) of patients had a clinical relapse in the B cell arm, compared with 20.5% (95% CI 11.9 to 34.1) in the ANCA arm, at 3 years after study entry (log-rank p=0.045). Total SAEs, including infectious SAEs, and deaths did not differ. The number of SAEs due to COVID-19 was higher in the B cell arm (p=0.049). In the B cell arm, patients received a mean of 3.6 (SD 2.4) infusions (3.6 g) per person over the median study follow-up time of 4.1 years, compared with 0.5 (SD 1.4) infusions (0.5 g) per patient in the ANCA arm (p<0.001).
    Conclusions: Rituximab dosed for B cell repopulation results in fewer clinical relapses than when dosed for a rise in ANCA level in maintenance of remission for ANCA vasculitis. Overall safety was equivalent; SAEs due to COVID-19 and rituximab exposure were higher with the B cell strategy.
    Trial registration number: NCT02749292.
    MeSH term(s) Humans ; Rituximab/therapeutic use ; Antibodies, Antineutrophil Cytoplasmic ; Prospective Studies ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy ; Remission Induction ; COVID-19 ; Recurrence ; Immunosuppressive Agents/adverse effects ; Treatment Outcome
    Chemical Substances Rituximab (4F4X42SYQ6) ; Antibodies, Antineutrophil Cytoplasmic ; Immunosuppressive Agents
    Language English
    Publishing date 2024-02-15
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/ard-2023-224489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020.

    Gupta, Shruti / Cortazar, Frank B / Riella, Leonardo V / Leaf, David E

    Kidney360

    2020  Volume 1, Issue 2, Page(s) 130–140

    Abstract: Immune checkpoint inhibitors (ICPIs) have transformed the landscape of oncology, but are associated with a variety of autoimmune adverse events, including AKI. ICPI-associated AKI (ICPI-AKI) is emerging as an increasingly frequent cause of AKI in ... ...

    Abstract Immune checkpoint inhibitors (ICPIs) have transformed the landscape of oncology, but are associated with a variety of autoimmune adverse events, including AKI. ICPI-associated AKI (ICPI-AKI) is emerging as an increasingly frequent cause of AKI in patients with cancer, and poses unique diagnostic and management challenges to clinicians who care for these patients. In this review, we describe the incidence and risk factors for ICPI-AKI, including proton pump inhibitor use, CKD, and combination immunotherapy. We discuss the limitations of the various definitions used for ICPI-AKI in prior studies, and propose a novel classification system (definite, probable, and possible ICPI-AKI) that recognizes the diagnostic uncertainty inherent in many cases. We discuss the key clinicopathologic features and treatment strategies for ICPI-AKI, including the role of kidney biopsy versus empirical treatment with steroids. We also explore the under-studied area of ICPI use in the setting of solid organ transplantation, where nephrologists and oncologists must balance the risk of rejection versus treating the underlying malignancy. Finally, we summarize existing data on the role of ICPI rechallenge after an episode of ICPI-AKI.
    MeSH term(s) Acute Kidney Injury/chemically induced ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immunotherapy/adverse effects ; Incidence ; Neoplasms/drug therapy
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2020-01-14
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural ; Review
    ISSN 2641-7650
    ISSN (online) 2641-7650
    DOI 10.34067/KID.0000852019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Case 34-2020: A 74-Year-Old Man with Chronic Kidney Disease.

    Cortazar, Frank B / Rhee, Eugene P / Gupta, Sumit / Sakhuja, Rahul / Stone, John H / Colvin, Robert B

    The New England journal of medicine

    2020  Volume 383, Issue 18, Page(s) 1768–1778

    MeSH term(s) Aged ; Aortic Valve Stenosis/complications ; Diagnosis, Differential ; Glomerulonephritis, Membranous/complications ; Glomerulonephritis, Membranous/diagnosis ; Humans ; Immunoglobulin G4-Related Disease/complications ; Immunoglobulin G4-Related Disease/diagnosis ; Kidney/pathology ; Lacrimal Apparatus/pathology ; Male ; Nephritis, Interstitial/complications ; Nephritis, Interstitial/diagnosis ; Orbital Pseudotumor/complications ; Orbital Pseudotumor/pathology ; Preoperative Care ; Renal Insufficiency, Chronic ; Transcatheter Aortic Valve Replacement
    Language English
    Publishing date 2020-10-28
    Publishing country United States
    Document type Case Reports ; Clinical Conference ; Journal Article
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMcpc2002415
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Renal Involvement in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

    Zonozi, Reza / Niles, John L / Cortazar, Frank B

    Rheumatic diseases clinics of North America

    2018  Volume 44, Issue 4, Page(s) 525–543

    Abstract: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is the most common cause of rapidly progressive glomerulonephritis. ANCAs play an important role in the pathogenesis and diagnosis of AAV. The classic renal lesion in AAV is a pauci-immune ... ...

    Abstract Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is the most common cause of rapidly progressive glomerulonephritis. ANCAs play an important role in the pathogenesis and diagnosis of AAV. The classic renal lesion in AAV is a pauci-immune necrotizing and crescentic glomerulonephritis. Treatment is divided into 2 phases: (1) induction of remission to eliminate disease activity and (2) maintenance of remission to prevent disease relapse. AAV patients with end-stage renal disease require modification of immunosuppressive strategies and consideration for kidney transplantation. An improved understanding of disease pathogenesis has led to new treatment strategies being tested in clinical trials.
    MeSH term(s) Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/complications ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/immunology ; Antibodies, Antineutrophil Cytoplasmic/blood ; Disease Progression ; Glomerulonephritis/diagnosis ; Glomerulonephritis/etiology ; Humans ; Immunosuppression/methods ; Prognosis ; Secondary Prevention
    Chemical Substances Antibodies, Antineutrophil Cytoplasmic
    Language English
    Publishing date 2018-09-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 92118-x
    ISSN 1558-3163 ; 0889-857X
    ISSN (online) 1558-3163
    ISSN 0889-857X
    DOI 10.1016/j.rdc.2018.06.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: IgG4-related disease and the kidney.

    Cortazar, Frank B / Stone, John H

    Nature reviews. Nephrology

    2015  Volume 11, Issue 10, Page(s) 599–609

    Abstract: ... effective options. B-cell depletion and the targeting of plasmablasts are both promising approaches. ...

    Abstract IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition that involves almost every organ system. In this Review, we summarize current knowledge of IgG4-RD and its most frequent manifestations in the kidney—IgG4-related tubulointerstitial nephritis (TIN) and membranous glomerulonephropathy (MGN). Diagnosis of IgG4-RD relies on histopathology: the typical features are a dense lymphoplasmacytic infiltrate and storiform fibrosis. A high percentage of plasma cells observed within lesions stain positively for IgG4. IgG4-related TIN bears the hallmark pathological findings of IgG4-RD; distinctive radiographic characteristics are also frequently observed with use of contrast-enhanced CT. MGN secondary to IgG4-RD seems to be distinct from idiopathic MGN. Humoral and cell-mediated immunity seem to have roles in the pathophysiology of IgG4-RD, but the details of these roles remain unclear. The IgG4 molecule itself is unlikely to be the primary driver of inflammation; rather, it probably downregulates the immune response. Fibrosis might be caused by activation of innate immune cells by polarized CD4(+) T cells. Glucocorticoids are the standard initial treatment for IgG4-RD, but their long-term adverse effects and the high frequency of relapse and renal damage associated with use of this treatment has prompted a search for more effective options. B-cell depletion and the targeting of plasmablasts are both promising approaches.
    MeSH term(s) Humans ; Immunoglobulin G/blood ; Kidney Diseases/blood ; Kidney Diseases/diagnosis ; Kidney Diseases/immunology ; Kidney Diseases/physiopathology ; Kidney Diseases/therapy ; Paraproteinemias/blood ; Paraproteinemias/complications ; Paraproteinemias/diagnosis ; Paraproteinemias/physiopathology ; Paraproteinemias/therapy
    Chemical Substances Immunoglobulin G
    Language English
    Publishing date 2015-10
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2490366-8
    ISSN 1759-507X ; 1759-5061
    ISSN (online) 1759-507X
    ISSN 1759-5061
    DOI 10.1038/nrneph.2015.95
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Treatment of Aggressive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Eculizumab.

    Huizenga, Noah / Zonozi, Reza / Rosenthal, Jillian / Laliberte, Karen / Niles, John L / Cortazar, Frank B

    Kidney international reports

    2019  Volume 5, Issue 4, Page(s) 542–545

    Language English
    Publishing date 2019-12-04
    Publishing country United States
    Document type Case Reports
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2019.11.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top